To: jayhawk969 who wrote ( 138) 1/18/2003 6:07:23 PM From: scaram(o)uche Read Replies (1) | Respond to of 146 Companies with "no way out" and which are receiving insufficient interest from investors should sell if they get a chance. JNJ is getting a bargain IMO. Shareholders may also be getting a good deal, relative to what it would have looked like in a year. I say "may", turning to the frustration of...... This is sort of like SIBIA, and we still hear, on occasion, that the secretase inhibitors are advancing. I still cuss when I hear something like that. Both investor's capital and jobs need to be maintained. I'm all for take-under-like deals if they are an expeditious solution to a "funding issue" that would become chronic. They will keep labs at work, focusing innovation at medicines without disruption. JNJ wants DDDP. That's good. We should want people to want our companies. And it's not substituting one Soap for another, HYSQ/VGNX. The SIBIA frustration was cast when valuations had reached low extremes, following one very rough summer. Immediately thereafter, we headed for a period of prolonged and ultimately over done respect for preclinical research and i.p., aka the bubble. Somewhere in between summer '98 and bubble would be nice. But..... companies with "no way out", given the current funding crisis? They should be shopping themselves to pharma. Congrats on those who had doubled down to the extent that the investment was sound and to those who got in at the lows. I'm not among your ranks. I was overweight SIBIA from a low basis when they went....... Message 10775419 Hope somebody was that lucky here. SIBI went during the tech rally, just as we were rolling toward biotech's version of the dotcom bubble. Preclinical research and i.p. are now discounted to a similar degree, and pharma needs it. I wish that pharma's pockets were deeper. Maybe Microsoft or IBM will diversify.